- Fellowship: Indiana University, Indianapolis
- Fellowship: McGill University, Montréal, Quebec
- Ph.D., Université de Montréal, Quebec
- M.Sc., Université de Montréal, Québec
- B.Sc., Faculté de Pharmacie, Université Laval, Québec
Veronique Michaud, B.Sc. Pharm, Ph.D., joined the University of Florida College of Pharmacy as an associate professor of pharmacotherapy and translational research in Jan. 2018. Based at the Lake Nona campus, Michaud aims to expand her clinical and research interests that include pharmacokinetics, drug-metabolism, drug-drug interactions, pharmacogenenomics and the study of intracellular drug-metabolism leading to modulation of drug action or side effects. Her research investigates the contribution of CYP450 drug-metabolizing enzymes in drug disposition, with a special attention to the role of disease state, focusing on type 2 diabetes (T2D) in a CYP450 isozyme-selective and a tissue-selective fashion. The aim of her research program is to provide a better understanding of factors responsible for intersubject variability in drug action and to provide tools to clinicians to improve treatments and reduce adverse drug events.
Prior to joining the UF College of Pharmacy, Michaud served as the vice president of scientific affairs at TabulaRasa Health Care in New Jersey. She has also worked as an assistant professor in a full research position and directed a pharmacokinetic and bioanalytic core facility at the University of Montreal Hospital Research Center. During her career, she has earned more than $22 million in research awards, published more than 30 peer-reviewed journal articles and mentored graduate students and Pharm.D. residents. She completed fellowships at Indiana University in Indianapolis and McGill University in Montreal and earned her Ph.D. and M.Sc. degrees from the Université de Montréal in Canada.
- Drug-drug interactions
- Drug metabolism
- Drug transporters
Michaud V, Bar-Magen T, Turgeon J, Desta Z, Flockhart D, Wainberg M. The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev.2012; 64 (3):803-33.
Michaud V, Ogburn E, Kreutz Y , Thong N, Aregbe AO., Quigg TC., Epstein N, Callaghan JT., Flockhart DA., Desta Z. Induction of CYP2C19 and CYP3A activities following repeated administration of efavirenz in human. Clin Pharmacol Ther. Mar 2012; 91 (3):475-82.
Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure, CYP3A5, ABCB1 and ABCG2 Genetic Polymorphisms, and Inflammatory Factors. Cri Care Med. 2013 Apr; 41(4):999-1008.
Turgeon J, Michaud V, Steffen L. Letter to the Editor: Polypharmacy in the Elderly- when good drugs lead to bad outcomes. A teachable moment (April 24, 2017; E1). JAMA Internal Medicine; 2017:177(10):1544.